Page 25 - FIMM_Brochure_2022
P. 25
Spinout company VEIL.AI Cancer precision medicine
company collaborations
VEIL.AI is a recently established spinout company from
FIMM researchers. VEIL.AI anonymisation engine is a Our precision medicine leaders at FIMM have long-
novel, powerful approach to de-identify personal or term collaborations with Celgene/BMS, Bayer,
otherwise sensitive data, facilitate data sharing and Novartis, Orion Pharma and Pfizer enabling clinical
analysis in low or zero-trust environments and ensure trials and drug discovery and development in Finland.
that neither anonymity nor data quality is compro- Based on our collaboration with US-based Celgene/
mised. BMS in preclinical cancer research, the HUS Compre-
hensive Cancer Centre has been selected as a site for
The VEIL.AI service enables potentially sensitive indi- a Celgene-sponsored early phase study in myeloma.
vidual-level information to be used in various research
and development projects as well as commercial ap- Most future clinical trials with new drugs will be
plications. VEIL.AI processes information without af- based on biomarkers. Identifying patient classifiers
fecting the value of collected data sets, ensuring that early, means that pharmaceutical companies can
individuals can no longer be identified. The application design smarter trials, with a higher probability of suc-
thus enables the information to be utilised for new cess. Smarter trials translate to a lower cost for drug
purposes and by new users. development, and eventually of new treatments. In
addition, patients can avoid drugs that will likely be
ineffective, resulting in better quality of life and more
rational use of resources.
FIMM – Building a Bridge from Discovery to Medicine | 25
